News
Disease, Function Predict Response to Rituximab
- Author:
- Sara Freeman
News
Gut Perforation Risk Is Low in Treated RA Patients
- Author:
- Sara Freeman
News
TRACTISS to Study Rituximab Effects in Sjögren's Syndrome
- Author:
- Sara Freeman
Major Finding: TRACTISS is expected to start patient recruitment in July 2011 and will investigate the use of rituximab vs. placebo for the...
News
BSRBR: Rituximab Effective; Disease Activity, Functional Status Predict Response
- Author:
- Sara Freeman
Major Finding: Mean change in DAS28 and HAQ scores from baseline to 6-months’ follow-up were –1.4 and –0.1, respectively, indicating reduced...
News
Antiviral Cidofovir May Enhance Therapies for HPV-Related Cancers
- Author:
- Sara Freeman
Major Finding: Cidofovir appears to increase the sensitivity of cervical carcinomas to the effects of radiotherapy and chemotherapy.
News
Antiviral Cidofovir May Enhance Therapies for HPV-Related Cancers
- Author:
- Sara Freeman
Major Finding: Cidofovir appears to increase the sensitivity of cervical carcinomas to the effects of radiotherapy and chemotherapy.
News
Intermittent Androgen Suppression Offers Small Gains for Prostate Cancer Patients
- Author:
- Sara Freeman
Major Finding: The frequency of hot flashes lessened markedly, with a 20-point difference in QOL scores at 2 years, but most QOL benefits were...
News
Intermittent Androgen Suppression Offers Small Gains for Prostate Cancer Patients
- Author:
- Sara Freeman
Major Finding: The frequency of hot flashes lessened markedly, with a 20-point difference in QOL scores at 2 years, but most QOL benefits were...
News
Intermittent Androgen Suppression Offers Small Gains for Prostate Cancer Patients
- Author:
- Sara Freeman
Major Finding: The frequency of hot flashes lessened markedly, with a 20-point difference in QOL scores at 2 years, but most QOL benefits were...
News
Larynx Preservation Studies Should Consider Treatment Impact
- Author:
- Sara Freeman
Major Finding: Considering all patients, the 5-year laryngoesophageal dysfunction-free survival (LED-FS) rate was just 28% and the 5-year freedom...
News
Low EGFR Expression Predicts ARCON Benefit in Laryngeal Cancer
- Author:
- Sara Freeman
Major Finding: The rates of 5-year locoregional control (88% vs. 71%) and disease-specific survival (91% vs. 78%) were better with low vs.
News
Low-Dose Irradiation Allays 93% of Gastric MALT Lymphomas at 10 Years
- Author:
- Sara Freeman
Major Finding: After a median of 5.5 years, the disease control rate was 98%.Data Source: Data representing 16 years of experience with the use of...
News
Low-Dose Irradiation Allays 93% of Gastric MALT Lymphomas at 10 Years
- Author:
- Sara Freeman
Major Finding: After a median of 5.5 years, the disease control rate was 98%.Data Source: Data representing 16 years of experience with the use of...
News
Fewer Side Effects From Proton Therapy in NSCLC
- Author:
- Sara Freeman
Major Finding: PBT resulted in significantly lower rates of grade 2 or higher esophagitis (P less than .0001), pneumonitis (P less than .002),...
News
Fewer Side Effects From Proton Therapy in NSCLC
- Author:
- Sara Freeman
Major Finding: PBT resulted in significantly lower rates of grade 2 or higher esophagitis (P less than .0001), pneumonitis (P less than .002),...